Increased efficacy and decreased systemic-effects of botulinum toxin A injection after active or passive muscle manipulation

Developmental Medicine and Child Neurology

Volumn 49, Issue 12, 2007, Pages 907-914

  Minamoto, Viviane B ^a   Hulst, Jonah B ^b   Lim, Michael ^b   Peace, William J ^b   Bremner, Shannon N ^b   Ward, Samuel R ^b   Lieber, Richard L ^c  

^a METHODIST UNIVERSITY OF PIRACICABA   (Brazil)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; ELECTROSTIMULATION THERAPY; MALE; MORPHOMETRICS; MUSCLE CELL; MUSCLE ISOMETRIC CONTRACTION; MUSCLE STRETCHING; NEUROMUSCULAR FUNCTION; NONHUMAN; PASSIVE MOVEMENT; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAT; SINGLE DRUG DOSE; SYSTEMIC DISEASE; TIBIALIS ANTERIOR MUSCLE; TORQUE; TOXICITY TESTING;

ANIMALS; BOTULINUM TOXIN TYPE A; INJECTIONS, INTRAMUSCULAR; MALE; MOVEMENT; MUSCLE CONTRACTION; MUSCLE FIBERS; MUSCLE, SKELETAL; NEUROMUSCULAR AGENTS; RANGE OF MOTION, ARTICULAR; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS;

EID: 36549062582     PISSN: 00121622     EISSN: 14698749     Source Type: Journal    
DOI: 10.1111/j.1469-8749.2007.00907.x     Document Type: Article

References (33)

1. Bayram S, Sivrioglu K, Karli N, Ozcan O. (2006) Low-dose botulinum toxin with short-term electrical stimulation in poststroke spastic drop foot: a preliminary study. Am J Phys Med Rehabil 85: 75-81.
2. Francisco GE, Boake C, Vaughn A. (2002) Botulinum toxin in upper limb spasticity after acquired brain injury: A randomized trial comparing dilution techniques. Am J Phys Med Rehabil 81: 355-363.
3. Koman LA, Brashear A, Rosenfeld S, Chambers H, Russman B, Rang M, Root L, Ferrari E, Garcia de Yebenes Prous J, Smith B P, et al. (2001) Botulinum toxin type a neuromuscular blockade in the treatment of equinus foot deformity in cerebral palsy: A multicenter, open-label clinical trial. Pediatrics 108: 1062-1071.
4. Chen R, Karp BI, Hallett M. (1998) Botulinum toxin type F for treatment of dystonia: Long-term experience. Neurology 51: 1494-1496.
5. Dodd SL, Selsby J, Payne A, Judge A, Dott C. (2005) Botulinum neurotoxin type A causes shifts in myosin heavy chain composition in muscle. Toxicon 46: 196-203.
6. Eleopra R, Tugnoli V, Caniatti L, De Grandis D. (1996) Botulinum toxin treatment in the facial muscles of humans: Evidence of an action in untreated near muscles by peripheral local diffusion. Neurology 46: 1158-1160.
7. Mancini F, Sandrini G, Moglia A, Nappi G, Pacchetti C. (2005) A randomised, double-blind, dose-ranging study to evaluate efficacy and safety of three doses of botulinum toxin type A (Botox) for the treatment of spastic foot. Neurol Sci 26: 26-31.
8. Hughes R, Whaler B. (1962) Influence of nerve-ending activity and of drugs on the rate or paralysis of rat diaphragm preparation by Cl. Botulinum type A toxin. J Physiol (London) 160: 221-233.
9. Black JD, Dolly JO. (1986) Interaction of 125I-labeled botulinum neurotoxins with nerve terminals. II. Autoradiographic evidence for its uptake into motor nerves by acceptor-mediated endocytosis. J Cell Biol 103: 535-544.
10. Frasson E, Priori A, Ruzzante B, Didone G, Bertolasi L. (2005) Nerve stimulation boosts botulinum toxin action in spasticity. Mov Disord 20: 624-629.
11. Eleopra R, Tugnoli V, De Grandis D. (1997) The variability in the clinical effect induced by botulinum toxin type A: The role of muscle activity in humans. Mov Disord 12: 89-94.
12. Chen R, Karp BI, Goldstein SR, Bara-Jimenez W, Yaseen Z, Hallett M. (1999) Effect of muscle activity immediately after botulinum toxin injection for writer's cramp. Mov Disord 14: 307-312.
13. Peters D, Barash IA, Burdi M, Yuan PS, Mathew L, Fridén J, Lieber RL. (2003) Asynchronous functional, cellular and transcriptional changes after a bout of eccentric exercise in the rat. J Physiol (London) 553: 947-957.
14. Hentzen E, Lahey M, Peters D, Mathew L, Barash I, Fridén J, Lieber R. (2006) Stress-dependent and stress-independent expression of the myogenic regulatory factors and the MARP genes after eccentric contractions. J Physiol (London) 570: 157-167.
15. Weibel ER. (1979) Stereological Methods. Vol 1 - Practical Methods for Biological Morphometry. London: Academic Press. pp 9-62, 101-161.
16. Sokal RR, Rohlf FJ. (1981) Biometry. San Francisco: WH Freeman and Company.
17. Draper NR, Smith H. (1981) Applied Regression Analysis. New York: John Wiley & Sons.
18. Dong M, Yeh F, Tepp WH, Dean C, Johnson EA, Janz R, Chapman ER. (2006) SV2 is the protein receptor for botulinum neurotoxin A. Science 312: 592-596.
19. Kim HS, Hwang JH, Jeong ST, Lee PKW, Shim JSS. (2003) Effect of muscle activity and botulinum toxin dilution volume on muscle paralysis. Dev Med Child Neurol 45: 200-206.
20. Carda S, Molteni F. (2005) Taping versus electrical stimulation after botulinum toxin type A injection for wrist and finger spasticity. A case-control study. Clin Rehabil 19: 621-626.
21. Molteni F. (1995) Botulinum toxin and rehabilitation programs in lower limb spasticity. Eur J Neurol 2: 61-67.
22. Hesse S, Jahnke MT, Luecke D, Mauritz KH. (1995) Short-term electrical stimulation enhances the effectiveness of Botulinum toxin in the treatment of lower limb spasticity in hemiparetic patients. Neurosci Lett 201: 37-40.
23. De Paiva A, Meunier F, Molgó J, Aoki K, Dolly O. (1999) Functional repair of motor endplates after botulinum neurotoxin type A poisoning: Biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc Natl Acad Sci USA 96: 3200-3205.
24. Booth F W. (1982) Effect of limb immobilization on skeletal muscle. J Appl Physiol 52: 1113-1118.
25. Pattullo M, Cotter M, Cameron N, Barry J. (1992) Effects of lengthened immobilization on functional and histochemical properties of rabbit tibialis anterior muscle. Exp Physiol 77: 433-442.
26. Caiozzo V, Haddad F, Baker M, Herrick R, Prietto N, Baldwin K. (1996) Microgravity-induced transformations of myosin isoforms and contractile properties of skeletal muscle. J Appl Physiol 81: 123-132.
27. Roy R, Bello M, Bouissou P, Edgerton R. (1987) Size and metabolic properties of fibers in rat fast-twitch muscles after hindlimb suspension. J Appl Physiol 62: 2348-2357.
28. Mitch WE, Goldberg AL. (1996) Mechanisms of muscle wasting. The role of the ubiquitin-proteasome pathway. N Engl J Med 335: 1897-1905.
29. Simard C P, Spector SA, Edgerton VR. (1982) Contractile properties of rat hindlimb muscles immobilized at different lengths. Exp Neurol 77: 467-482.
30. Spector SA, Gardiner PF, Zernicke RF, Roy RR, Edgerton VR. (1980) Muscle architecture and force-velocity characteristics of the cat soleus and medial gastrocnemius: Implications for motor control. J Neurophysiol 44: 951-960.
31. Lieber RL, Steinman S, Barash IA, Chambers H. (2004) Structural and functional changes in spastic skeletal muscle. Muscle Nerve 29: 615-627.
32. Wright J, Rang M. (1990) The spastic mouse. And the search for an animal model of spasticity in human beings. Clin Orthop Relat Res 253: 12-19.
33. Wickiewicz TL, Roy RR, Powell PL, Edgerton VR. (1983) Muscle architecture of the human lower limb. Clin Orthop Rel Res 179: 275-283.